Nancy Dezutter

1.1k total citations · 1 hit paper
11 papers, 485 citations indexed

About

Nancy Dezutter is a scholar working on Epidemiology, Immunology and Infectious Diseases. According to data from OpenAlex, Nancy Dezutter has authored 11 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 4 papers in Immunology and 3 papers in Infectious Diseases. Recurrent topics in Nancy Dezutter's work include Respiratory viral infections research (10 papers), Pneumonia and Respiratory Infections (6 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Nancy Dezutter is often cited by papers focused on Respiratory viral infections research (10 papers), Pneumonia and Respiratory Infections (6 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Nancy Dezutter collaborates with scholars based in Belgium, United States and Spain. Nancy Dezutter's co-authors include Marie‐Pierre David, Nathalie De Schrevel, Dong‐Gun Lee, Laurence Fissette, Lusiné Kostanyan, Isabel Leroux‐Roels, Tino F. Schwarz, Richard N. van Zyl-Smit, Federico Martinón‐Torres and Joanne M. Langley and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Science Translational Medicine.

In The Last Decade

Nancy Dezutter

9 papers receiving 467 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

2023 405 citations Alberto Papi, Michael G. Ison et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nancy Dezutter Belgium	6	396	189	125	50	49	11	485
Nathalie De Schrevel Belgium	7	432 1.1×	200 1.1×	122 1.0×	34 0.7×	45 0.9×	16	497
Lusiné Kostanyan United States	6	392 1.0×	184 1.0×	112 0.9×	28 0.6×	42 0.9×	9	456
Veronica Hulstrøm Belgium	7	422 1.1×	196 1.0×	128 1.0×	28 0.6×	41 0.8×	17	498
Nawarat Posuwan Thailand	15	551 1.4×	155 0.8×	34 0.3×	27 0.5×	30 0.6×	36	699
Athanasios Kossyvakis Greece	12	198 0.5×	186 1.0×	34 0.3×	44 0.9×	26 0.5×	26	404
Megan E. Schmidt United States	7	241 0.6×	233 1.2×	77 0.6×	65 1.3×	196 4.0×	12	496
Andreu Comas‐García Mexico	13	265 0.7×	181 1.0×	74 0.6×	33 0.7×	54 1.1×	32	431
Yu Mao China	6	400 1.0×	195 1.0×	37 0.3×	36 0.7×	71 1.4×	11	523
José García-Sicilia Spain	14	452 1.1×	63 0.3×	35 0.3×	13 0.3×	67 1.4×	21	519

Countries citing papers authored by Nancy Dezutter

Since Specialization

Citations

This map shows the geographic impact of Nancy Dezutter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nancy Dezutter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nancy Dezutter more than expected).

Fields of papers citing papers by Nancy Dezutter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nancy Dezutter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nancy Dezutter. The network helps show where Nancy Dezutter may publish in the future.

Co-authorship network of co-authors of Nancy Dezutter

This figure shows the co-authorship network connecting the top 25 collaborators of Nancy Dezutter. A scholar is included among the top collaborators of Nancy Dezutter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nancy Dezutter. Nancy Dezutter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Ison, Michael G., Alberto Papi, Eugene Athan, et al.. (2025). Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine. 13(6). 517–529. 12 indexed citations

Clark, Rebecca A., S. T. Davies, Jorge Labrador, et al.. (2024). Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion F Protein Vaccine when Co-administered with Adjuvanted Seasonal Quadrivalent Influenza Vaccine in Older Adults: A Phase 3 Randomized Trial. Clinical Infectious Diseases. 79(4). 1088–1098. 8 indexed citations

Smedt, Jonathan De, Vera Rocha‐Perugini, Edison Ong, et al.. (2023). The RSVPreF3-AS01 vaccine elicits broad neutralization of contemporary and antigenically distant respiratory syncytial virus strains. Science Translational Medicine. 15(710). eadg6050–eadg6050. 16 indexed citations

Ison, Michael G., Alberto Papi, Joanne M. Langley, et al.. (2023). A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Diabetologie und Stoffwechsel. 18(S 01). S54–S54. 2 indexed citations

Ison, Michael G., Alberto Papi, Joanne M. Langley, et al.. (2023). 1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons. Open Forum Infectious Diseases. 10(Supplement_2). 4 indexed citations

Warter, Lucile, et al.. (2023). Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models. npj Vaccines. 8(1). 143–143. 10 indexed citations

Papi, Alberto, Michael G. Ison, Joanne M. Langley, et al.. (2023). Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal of Medicine. 388(7). 595–608. 405 indexed citations breakdown →

Ison, Michael G., Alberto Papi, Joanne M. Langley, et al.. (2022). LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Open Forum Infectious Diseases. 9(Supplement_2). 5 indexed citations

Andrews, Charles P., Matthew Davis, Philippe De Smedt, et al.. (2020). 121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic. Open Forum Infectious Diseases. 7(Supplement_1). S188–S189.

10.

Andrews, Charles P., Matthew Davis, Brandon Essink, et al.. (2020). 119. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated. Open Forum Infectious Diseases. 7(Supplement_1). S187–S188. 1 indexed citations

11.

Dezutter, Nancy, et al.. (2011). High-Throughput Screening of Excipients Intended to Prevent Antigen Aggregation at Air-Liquid Interface. Pharmaceutical Research. 28(7). 1591–1605. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact